Daniel Sweeney

As an Associate in the Healthcare vertical, Daniel helps the team review and analyze prospective investment opportunities and present recommendations, focusing on the firm’s Identified Sector Opportunities (ISOs). He also collaborates with the Strategic Resource Group and portfolio company management to support existing investments through the next phase of growth.

Before joining the THL team, Daniel worked at Guggenheim Securities as an Investment Banking Analyst in the Healthcare Services Group. In his free time, he enjoys running, soccer, traveling and college football.

Verticals: Healthcare (HC)

Verticals: Healthcare (HC)

Related content

Press Release

Red Nucleus Announces Majority Investment from THL Partners

Strategic Investment Will Support Expanded Offerings for Company’s Global Customer Base Industry Veteran Mike Menta to Serve as Chief Executive Officer YARDLEY, PENNSYLVANIA, October 17, 2024/ Red Nucleus ( “the Company”), a leading provider of strategic services across research and development, medical affairs, market access, and learning and development, today announced that it has received a majority

October 17, 2024

Insights

Navigating the Complexities of the Specialty Drug Market

Challenges, Opportunities, and Insights from Asembia’s AXS24 Conference Key Takeaways: The specialty drug market is experiencing rapid growth and there is increasing commercial optimism in the space. There are clear opportunities to streamline drug delivery and improve patient access and adherence. To address the complexities of the specialty drug market —pricing, reimbursement, and access, to name a few

Healthcare (HC)